ULIXERTINIB
Ulixertinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target mitogen-activated protein kinase 3 and mitogen-activated protein kinase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 4 | — | — | — | 5 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | 1 | 4 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 3 | — | — | — | 4 |
| Melanoma | D008545 | — | — | 1 | 2 | — | — | 1 | 4 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | 1 | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | 1 | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 1 | — | — | 1 | 2 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | 1 | 2 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | 1 | 2 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | — | — | 1 | 2 |
Show 43 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Digestive system neoplasms | D004067 | — | — | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | — | — | 1 | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | — | 1 | 1 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ULIXERTINIB |
| INN | ulixertinib |
| Description | Ulixertinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target mitogen-activated protein kinase 3 and mitogen-activated protein kinase 1. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: epidermal growth factor receptor (EGFR) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 869886-67-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3590106 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 16ZDH50O1U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
MAPK3
MAPK3
MAPK1
MAPK1
Organism
Homo sapiens
Gene name
MAPK3
Gene synonyms
ERK1, PRKM3
NCBI Gene ID
Protein name
mitogen-activated protein kinase 3
Protein synonyms
ERK-1, ERT2, Extracellular signal-regulated kinase 1, extracellular signal-related kinase 1, Insulin-stimulated MAP2 kinase, MAP kinase isoform p44, MAPK 1, Microtubule-associated protein 2 kinase, p44-ERK1, p44-MAPK
Uniprot ID
Mouse ortholog
Mapk3 (26417)
mitogen-activated protein kinase 3 (Q91YW5)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 767 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use